menu
    • menu

    Company profile for Aptinyx

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate — rather than block or over-activate — NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. We believe l...
    Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate — rather than block or over-activate — NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. We believe leveraging the therapeutic advantages of this differentiated mechanism will drive a paradigm shift in the treatment of numerous disorders of the brain and nervous system.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AptinyxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    909 Davis Street, Suite 600 Evanston, IL 60201
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aptinyx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aptinyx-inc-/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Remember that record biotech IPO party in 2018? no ‘happily ever after’
    Remember that record biotech IPO party in 2018? no ‘happily ever after’

    08 May 2023

    // ENDPTS

    https://endpts.com/remember-that-record-biotech-ipo-party-in-2018-there-was-no-happily-ever-after/

    ENDPTS
    08 May 2023
    Share Share
    Aptinyx evaluates future of the company following two failed trials, 60% layoffs
    Aptinyx evaluates future of the company following two failed trials, 60% layoffs

    31 Mar 2023

    // Katherine Lewin ENDPTS

    https://endpts.com/aptinyx-evaluates-future-of-the-company-following-two-failed-trials-60-layoffs/

    Katherine Lewin ENDPTS
    31 Mar 2023
    Share Share
    Aptinyx Reports on 4Q and Full Year 2022 Results
    Aptinyx Reports on 4Q and Full Year 2022 Results

    30 Mar 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230330005712/en

    BUSINESSWIRE
    30 Mar 2023
    Share Share
    Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop
    Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop

    28 Feb 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/aptinyx-reeling-series-setbacks-dumps-dementia-drug-stops-ptsd-trial-after-phase-2-flop

    Nick Paul Taylor FIERCE BIOTECH
    28 Feb 2023
    Share Share
    Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment
    Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment

    27 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230227005764/en

    BUSINESSWIRE
    27 Feb 2023
    Share Share
    Aptinyx to Present at the SVB Securities Global Biopharma Conference
    Aptinyx to Present at the SVB Securities Global Biopharma Conference

    31 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230131005510/en

    BUSINESSWIRE
    31 Jan 2023
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search